Enhabit Inc EHAB R2K
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 29.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -0.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EHAB Enhabit Inc R2K | 13.80 | - | $706.91M | - | 3.40% | -0.19% | -0.35% | 29.54% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 286.10M | 273.90M | 274.30M | 268.00M | 265.70M | 265.10M | 262.30M | 258.30M | 262.40M | 260.60M | - | - | 259.90M | 266.10M | 263.60M | 270.40M | 264.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 130.20M | 135.50M | 135.80M | 138.70M | 134.20M |
| Gross Profit | 156.50M | 142.70M | - | 137.70M | 133.40M | - | - | - | - | - | - | - | 129.70M | 130.60M | 127.80M | 131.70M | 130.60M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 113.80M | 113.90M | 111.00M | 117.30M | 101.30M |
| Operating Income | 41.40M | 29.10M | 35.40M | 27.30M | 17.90M | 14.20M | -74.50M | 7.80M | 12.90M | 11.20M | - | - | 15.90M | 16.70M | 16.80M | 14.40M | 29.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 41.50M | 22.40M | 22.20M | -28.20M | 37.60M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 9.40M | 8.70M | 8.30M | 7.60M | 10.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | 25.80M | 8.00M | 8.40M | -40.80M | 23.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 7.40M | 2.30M | -3.20M | -2.50M | 3.10M |
| Net Income | 32.30M | 21.60M | 26.10M | 20.10M | 8.60M | 2.70M | -74.40M | -2.40M | 200.00K | -200.00K | - | - | 17.80M | 5.20M | 11.10M | -38.70M | 19.20M |
| Diluted EPS | 0.65 | 0.44 | 0.53 | 0.41 | 0.17 | 0.05 | -1.49 | -0.05 | 0.01 | 0.00 | - | - | 0.35 | 0.10 | 0.22 | -0.76 | 0.37 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.08B | - | 1.07B | 1.05B | 1.03B | 1.06B |
| Cost of Revenue | - | - | 525.60M | 535.60M | 530.80M | 540.20M |
| Gross Profit | - | - | 545.50M | 510.70M | 504.00M | 519.80M |
| Operating Expenses | - | - | 447.90M | 472.50M | 457.40M | 456.00M |
| Operating Income | 102.70M | - | 97.60M | 38.20M | 46.60M | 63.80M |
| EBITDA | - | - | 22.50M | -16.50M | -83.60M | 57.90M |
| Interest Expense | - | - | 15.00M | 43.00M | 42.90M | 34.00M |
| Pretax Income | - | - | -25.50M | -90.40M | -158.00M | 1.40M |
| Tax Provision | - | - | 12.80M | -11.40M | -4.00M | 4.00M |
| Net Income | 75.00M | - | -40.40M | -80.50M | -156.20M | -4.60M |
| Diluted EPS | 1.51 | 2.23 | 1.26 | -1.61 | -3.11 | - |
Compounded Sales Growth
| 5 Years: | -0.35% |
| 1 Year: | 1.90% |
Compounded Profit Growth
| 5 Years: | 29.54% |
| 1 Year: | 2.90% |
Stock Price Performance
| 1 Year: | +31.43% |
| 6 Months: | +72.72% |
| 3 Months: | +22.99% |
| 1 Month: | +0.66% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 1.53B | 1.43B | 1.23B | 1.17B |
| Current Assets | - | - | - | 211.80M | 210.10M | 192.70M | 205.60M |
| Cash & Equivalents | - | - | - | 22.90M | 27.40M | 28.40M | 43.60M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 149.60M | 164.70M | 149.20M | 144.00M |
| Total Liabilities | - | - | - | 751.50M | 731.90M | 672.10M | 603.00M |
| Current Liabilities | - | - | - | 132.90M | 137.70M | 126.20M | 126.30M |
| Long Term Debt | - | - | - | 560.00M | 530.10M | 492.60M | 426.00M |
| Total Debt | - | - | - | 625.20M | 610.10M | 569.50M | 500.00M |
| Total Equity | 658.50M | 1.39B | - | 741.70M | 669.70M | 523.50M | 534.00M |
| Shares Outstanding | - | - | - | 50.10M | 50.17M | 50.59M | 51.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.90M | - | 80.10M | 48.40M | 51.20M | 70.70M |
| Investing Cash Flow | -3.00M | - | -42.30M | -5.30M | -2.40M | 16.70M |
| Financing Cash Flow | -16.70M | - | -18.60M | -40.50M | -48.30M | -72.20M |
| Capital Expenditure | -3.20M | - | -7.10M | -3.50M | -3.80M | -4.90M |
| Free Cash Flow | 21.70M | - | 73.00M | 44.90M | 47.40M | 65.80M |
| Net Change in Cash | - | - | 19.20M | 2.60M | 500.00K | 15.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 50.9% | 48.8% | 48.7% | 49.0% |
| Operating Margin % | 9.5% | - | 9.1% | 3.7% | 4.5% | 6.0% |
| Net Margin % | 7.0% | - | -3.8% | -7.7% | -15.1% | -0.4% |
| ROE % | 5.4% | - | -5.4% | -12.0% | -29.8% | -0.9% |
| ROCE % | - | - | 7.0% | 2.9% | 4.2% | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | 8 Knots Management, LLC | 9.93% | 5.08M | $70.17M |
| 2 | Deerfield Management Company, L.P | 9.27% | 4.75M | $65.52M |
| 3 | Blackrock Inc. | 7.54% | 3.86M | $53.32M |
| 4 | Arex Capital Management, Lp | 4.87% | 2.49M | $34.42M |
| 5 | Vanguard Capital Management LLC | 4.17% | 2.14M | $29.50M |
| 6 | UBS Group AG | 4.12% | 2.11M | $29.10M |
| 7 | Jana Partners Management, Lp | 4.08% | 2.09M | $28.85M |
| 8 | Paradice Investment Management, LLC | 3.21% | 1.64M | $22.69M |
| 9 | Dimensional Fund Advisors LP | 2.91% | 1.49M | $20.59M |
| 10 | Geode Capital Management, LLC | 2.32% | 1.19M | $16.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EHAB